Benefits and Challenges of a Digital Exercise and Mind-Body Program During Active Cancer Treatment: Qualitative Study of Patients' Perceptions.
Karolina L Bryl, Sierra Silverwood, Krupali Desai...
https://pubmed.ncbi.nlm.nih.gov/41543884Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID05053230
Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE) Program Evaluating Virtual Mind-Body Support During Cancer Treatment
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-10-09
480
Participants Needed
7
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the Integrative Medicine at Home (IM@Home) program to see if it improves patient-reported values, outcomes, and experiences for people undergoing systemic cancer treatments such as chemotherapy, immunotherapy, radiotherapy, targeted agents, or cytoreductive surgery. This program is part of the IMPROVE research initiative and focuses on patients with various cancers including head and neck, thoracic, gynecologic, melanoma, breast, and ovarian cancers. The goal is to assess how virtual mind-body therapies may support cancer patients during their treatment journey. Participants will be randomly assigned to either the IM@Home group or an enhanced usual care group. Those in the IM@Home group will take part in a 12-week virtual program offering weekly synchronous mind-body and fitness classes via Zoom, led by trained therapists with oncology expertise. Classes include activities such as fitness, yoga, dance therapy, tai chi, meditation, guided meditation, and music therapy. Each session lasts 30 to 45 minutes, with time for feedback and discussion. The enhanced usual care group will receive standard care plus access to pre-recorded meditation and relaxation resources. During the 12 weeks, participants will be monitored through patient-reported assessments measuring fatigue severity, symptom intensity, insomnia, psychological distress, pain, treatment expectancy, satisfaction, and session attendance. Researchers will also track treatment disruptions and unplanned medical visits. These evaluations will help determine the impact of the IM@Home program on patient well-being and treatment experience throughout the study period.
CONDITIONS
Brief Title
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Karnofsky score 60 or greater
- Life expectancy greater than six months
- English speaking
- Diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer
- Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery
- Worst fatigue over the last 7 days rated 4 or greater on a 0-10 scale
- For first remission gynecologic cancer: completed definitive first line treatment (maintenance hormonal or targeted therapies allowed)
- For advanced cancer basket: diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer; unresectable cholangiocarcinoma, liver, ampullary, peri-ampullary cancer; other stage IV gastrointestinal, ovarian, fallopian tube, gynecologic, breast, testicular, genitourinary, sarcoma, melanoma, endocrine cancers; lymphoma, myeloma, or leukemia
- For cancer survivor basket: completed active cancer treatment (maintenance hormonal or targeted therapies allowed) with fatigue rated 4 or greater
You will not qualify if you...
- Cognitive impairment preventing response to study assessments or requiring legally authorized representatives
- Unwillingness to accept random assignment
- Concurrent enrollment in other integrative medicine trials with symptom/toxicity as primary outcome (other therapeutic protocols allowed)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 weeks
Participants receive either a 12-week virtual mind-body and fitness program with weekly classes or enhanced usual care with access to on-demand meditation resources.
Weekly virtual classes 1 to 4 times per week or access to online resources after enrollment
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Loading map...
Research Team
K
Karolina Bryl, PhD
M
Michael Postow, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment.
Jun J Mao, Karolina Bryl, Erin F Gillespie...
https://pubmed.ncbi.nlm.nih.gov/39809874